• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Engineered AAV Vectors Target Neuroblastoma Cells via Antibody Coupling

by
November 8, 2026
in Health
Reading Time: 5 mins read
0
Engineered AAV Vectors Target Neuroblastoma Cells via Antibody Coupling

Engineered AAV Vectors Target Neuroblastoma Cells via Antibody Coupling

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have developed a modular platform that redirects the natural tissue tropism of adeno-associated virus (AAV) vectors to specifically target neuroblastoma cells. Published in EMBO Molecular Medicine, the study introduces AAV-STITCH, a strategy that uses SpyTag technology to covalently attach antibody fragments directly to the AAV capsid. By coupling an anti-GD2 single-chain variable fragment (scFv) to a galactose-binding-deficient AAV9-W503A capsid, the team created a vector that selectively transduces GD2-expressing neuroblastoma cells while largely abolishing infection of healthy tissues. This approach addresses a significant limitation of standard AAV gene therapy, where broad tropism often leads to off-target transduction and limits the precision required for tumor-specific applications.

The development of AAV-STITCH addresses the challenge of achieving cell-type specific viral transduction in cancer. While AAVs are widely used in gene therapy for their versatility and safety, their native serotypes exhibit broad infectivity across multiple tissues. Previous attempts to modify AAV capsids through peptide fusions or click chemistry have often resulted in reduced viral yield or complex, multi-step workflows. The AAV-STITCH platform leverages the high-affinity isopeptide bond formed between SpyTag and SpyCatcher domains to enable efficient and specific covalent coupling of polypeptides to the viral surface. This method allows for the precise, dose-dependent coupling of targeting molecules, providing a versatile framework for engineering AAVs with highly specific transduction properties.

To establish an effective and modular approach, the researchers integrated the SpyTag sequence into the variable region IV of the AAV9 capsid. They selected the AAV9-W503A mutant capsid, which is almost fully deficient in cellular infectivity due to the abolition of its binding to galactose. This mutant serves as a neutral packaging vector, ensuring that the viral tropism is dictated solely by the peptides grafted onto its surface. The anti-GD2 scFv was fused to the SpyCatcher domain, creating a construct that could be covalently linked to the SpyTag-modified capsid. The team compared two production strategies: post-production coupling, where purified viral particles and antibody fragments are incubated together, and co-expression coupling, where the components are produced simultaneously in HEK293T cells.

The co-expression coupling strategy proved significantly more efficient than the post-production method. Post-production coupling required extremely high ratios of antibody to virus for detectable conjugation and resulted in substantial amounts of unbound protein. In contrast, the co-expression protocol facilitated efficient covalent coupling with minimal unbound protein after purification. This approach also avoided unwanted post-translational modifications, such as glycosylation, that were observed in the secreted antibody fragments. The co-expression method bypassed the need for labor-intensive protein purification, streamlining the vector generation process and enhancing reproducibility. Based on these results, the researchers adopted the co-expression method for all subsequent experiments, demonstrating that the platform can be scaled for broader applications.

Initial characterization revealed that high density of antibody molecules on the viral surface could create steric hindrance, interfering with viral entry. To optimize transduction efficiency, the team generated mosaic capsids by mixing plasmids containing or lacking the SpyTag sequence at defined ratios. The 1:3 mosaic configuration, which reduced the number of conjugated antibody molecules per capsid, resulted in the highest transduction rate in vitro. This configuration was designated as AAV-STITCHαGD2. The vector efficiently transduced GD2-positive neuroblastoma cell lines, including SH-SY5Y, LAN-5, IMR-42, and HTLA-230, while GD2-negative cells remained resistant to transduction. These findings confirmed the antigen-dependent mechanism of cell targeting and the specificity of the capsid conjugation.

In vivo studies in wild-type C57BL/6 mice demonstrated that AAV-STITCHαGD2 showed negligible infection of healthy tissues normally transduced by native AAV9, including liver, heart, muscles, brain, and lungs. The only notable exception was the dorsal root ganglia (DRG) neurons, which were partially transduced, consistent with previous reports of GD2 expression in this neuronal population. In a pseudometastatic neuroblastoma xenograft mouse model, AAV-STITCHαGD2 selectively transduced tumor cells in the liver without transducing the surrounding healthy hepatic parenchyma. In contrast, wild-type AAV9 preferentially transduced hepatocytes, with minimal signal in metastatic foci. This selective targeting highlights the potential of the platform to minimize off-target effects while maximizing tumor-specific gene delivery.

To evaluate therapeutic efficacy, the researchers packaged a modified Herpes Simplex Virus thymidine kinase gene (HSV-TK) into AAV-STITCHαGD2. This suicide gene system induces irreversible apoptotic cell death in proliferating cells upon treatment with ganciclovir. In subcutaneous xenograft models, AAV-STITCHαGD2-TK robustly suppressed tumor growth compared to control vectors. Histological inspection confirmed a marked reduction in tumor size in the treated group. Behavioral and functional analyses indicated no detectable impairment of DRG neuronal function, supporting the safety profile of the approach. Systemic analyses revealed no alterations in blood cell counts or liver enzyme levels, further confirming the absence of significant toxicity.

The combination of AAV-STITCHαGD2-TK with standard-of-care chemotherapy (TOTEM) produced additive antitumor effects. In subcutaneous xenograft models, the combined treatment reduced tumor burden to almost undetectable levels, with a greater reduction than either monotherapy alone. These results demonstrate the complementary mechanisms of action between the targeted gene therapy and conventional chemotherapy. In a patient-derived xenograft model, AAV-STITCHαGD2-TK also showed potent antitumor activity, suppressing the growth of primary human neuroblastoma tissue. These findings highlight the translational potential of the platform for treating high-risk neuroblastoma, where current therapies often face limitations due to the immunosuppressive tumor microenvironment.

The AAV-STITCH platform offers a generalizable strategy for converting broadly tropic AAV vectors into precision gene-delivery vehicles for cancer. The modular nature of the system allows for the coupling of different antibodies to target various disease-specific surface antigens. The researchers demonstrated the versatility of the platform by generating an AAV-STITCH variant targeting HER2, which mediated robust gene transfer in HER2-positive breast cancer cell lines. This adaptability suggests that the platform can be applied to a wide range of solid malignancies. By enabling selective systemic delivery of therapeutic genes while minimizing off-target transduction, AAV-STITCH establishes a new framework for safer and more effective precision viral therapies.

Despite these promising results, several limitations remain. The progressive dilution of the episomal viral vector in proliferating tumor cells can lead to a gradual loss of therapeutic efficacy over time. Additionally, the development of neutralizing antibodies against the viral capsid and the SpyTag/SpyCatcher components may restrict repeated administration. However, the study suggests that a single treatment can provide long-lasting survival benefits in aggressive xenograft models. The ability of AAVs to infect non-dividing cells may also allow for the targeting of quiescent cancer stem cells, which are thought to promote resistance to standard therapies. Future efforts should aim to implement additional detargeting strategies to further minimize potential off-target effects in peripheral tissues and to optimize the platform for clinical application.

The development of AAV-STITCH represents a significant advance in the field of targeted gene therapy. By leveraging SpyTag/SpyCatcher chemistry, the researchers have created a streamlined workflow for generating antibody-conjugated AAV vectors with high specificity and efficiency. The platform addresses longstanding challenges in AAV engineering, such as the need for cell-type specific transduction and the reduction of off-target effects. The successful application of AAV-STITCHαGD2 in neuroblastoma models provides a compelling proof-of-concept for its use in other cancers. As the field moves toward precision oncology, the AAV-STITCH platform offers a versatile tool for developing next-generation gene therapies that can be tailored to specific tumor antigens.

Subject of Research: Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling

Article Title: Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling

Article References: Luoni, M., Parracino, S., Giannelli, S. G., Morosi, F., Ventura, E., Di Pizio, A., Muggeo, S., Iannielli, A., Sicardi, S., Canu, T., Russo, T., Esposito, A., Del Carro, U., Pastorino, F., & Broccoli, V. (2026). Targeted AAV gene therapy for neuroblastoma via direct capsid-antibody coupling. EMBO Molecular Medicine, 18(10), 4117-4152. https://doi.org/10.1038/s44321-026-00520-7

Image Credits: AI Generated

DOI: 10.1038/s44321-026-00520-7

Keywords: Targeted, gene, therapy, neuroblastoma, direct, capsid-antibody, coupling, scientific research

News Source: Ophelia Keating. (November 8, 2026). Engineered AAV Vectors Target Neuroblastoma Cells via Antibody Coupling. Scienmag.

Tags: capsid-antibodycouplingdirectgeneNeuroblastomascientific researchTargetedtherapy
Share12Tweet7Share2ShareShareShare1

Related Posts

Study Finds Nearly Half of Ethiopian PACU Patients Experience Discharge Delays

Study Finds Nearly Half of Ethiopian PACU Patients Experience Discharge Delays

November 18, 2026
Scoping Review Finds Low Certainty for Light Therapies in HIV Symptom Relief

Scoping Review Finds Low Certainty for Light Therapies in HIV Symptom Relief

November 18, 2026

Early Postoperative Biomarkers Predict Pancreatic Fistula Risk Following Distal Pancreatectomy

November 18, 2026

Machine Learning Identifies Nine-Gene Macrophage Signature Predicting Lung Adenocarcinoma Prognosis

November 18, 2026

POPULAR NEWS

  • Coal Gangue Aggregates Can Replace Natural Stone in Concrete Applications

    Coal Gangue Aggregates Can Replace Natural Stone in Concrete Applications

    29 shares
    Share 12 Tweet 7
  • Cluster-Based Training Selection Outperforms Active Learning for Material Property Prediction

    29 shares
    Share 12 Tweet 7
  • Cesarean Section Rates Reached Forty Percent Among Surveyed Mothers in Njombe Region

    29 shares
    Share 12 Tweet 7
  • Testosterone Injections Exacerbate Pre-Neoplastic Prostate Lesions in NKX3.1-Deficient Mice

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study Finds Nearly Half of Ethiopian PACU Patients Experience Discharge Delays

Scoping Review Finds Low Certainty for Light Therapies in HIV Symptom Relief

Copy Number Analysis Enhances Chromosomal Detection in Fetuses With Non-Isolated Ventriculomegaly

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.